Best Peptide Therapy in Ohio: 2026 Guide

Last updated: April 2026

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Peptide therapies should only be administered under the supervision of a licensed healthcare provider. Always consult your physician before starting any new treatment protocol.

Affiliate Disclosure: Peptide Front may earn a commission from products linked in this article. This does not influence our editorial recommendations.

Ohio has become one of the more active states for peptide therapy in the Midwest. Between the regulatory shifts happening at the federal level and the Ohio State Board of Pharmacy's own 2026 clarifications, patients across the Buckeye State have more options than they did even 12 months ago. But more options also means more confusion. Which clinics are legitimate? What do treatments actually cost? And what changed with the law?

This guide breaks it all down. No fluff, no hype -- just what you need to know if you're considering peptide therapy in Ohio right now.

What Is Peptide Therapy and Why Is Ohio a Growing Market?

Peptide therapy uses short chains of amino acids -- typically between 2 and 50 -- to signal specific biological processes in the body. Unlike traditional pharmaceuticals that often work by blocking or suppressing a pathway, peptides generally work by mimicking or amplifying the body's own signaling molecules. That distinction matters. It's why peptides have attracted interest from everyone from aging Baby Boomers to collegiate athletes recovering from injury.

Ohio specifically has seen notable growth in peptide therapy adoption. The state's population of 11.8 million (U.S. Census Bureau, 2025 estimate) skews older than the national average, with 18.2% of residents aged 65 or older. That demographic reality creates genuine demand for therapies targeting age-related decline -- muscle loss, slower recovery, poor sleep quality, and hormonal shifts.

According to a 2025 report from Grand View Research, the global peptide therapeutics market was valued at approximately $49.1 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.66% through 2030. The U.S. accounts for the largest share of that market, and states like Ohio with robust healthcare infrastructure and aging populations are driving domestic demand.

Dr. Rebecca Harmon, MD, an integrative medicine physician based in Columbus, puts it plainly: "We've seen a 40% increase in peptide therapy inquiries at our practice since 2024. Patients are doing their own research and coming in asking about specific peptides by name -- BPC-157 for joint pain, sermorelin for sleep and recovery. The awareness level has shifted dramatically."

Ohio also benefits from having multiple 503A and 503B compounding pharmacies operating within state lines. That local infrastructure means shorter shipping times, fresher compounds, and easier oversight compared to states where patients must source peptides from out-of-state facilities.

The Cleveland Clinic -- one of the top-ranked hospital systems in the world -- has expanded its integrative medicine offerings to include peptide-related consultations, lending mainstream credibility to what was once considered fringe. Cincinnati's major health systems have followed, and Columbus has emerged as a hub for private peptide therapy practices.

For patients exploring GH peptides and their role in muscle growth and recovery, Ohio's combination of regulatory clarity, medical infrastructure, and growing provider networks makes it one of the better states to pursue treatment in 2026.

How Have Ohio's Peptide Therapy Regulations Changed in 2026?

The regulatory picture for peptide therapy has shifted significantly -- both nationally and within Ohio specifically. Understanding these changes is essential before you walk into any clinic.

At the federal level, the biggest development came on February 27, 2026, when HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously classified as Category 2 restricted substances would be reclassified back to Category 1 status. This includes some of the most widely used peptides in clinical practice: BPC-157, TB-500 (Thymosin Beta-4), CJC-1295, Ipamorelin, and Sermorelin. NPR reported on this announcement, noting it as a significant reversal from the FDA's previous restrictive posture.

Category 1 status means these peptides can once again be legally compounded by both 503A (traditional) and 503B (outsourcing facility) pharmacies for individual patient use, provided a valid prescription exists. This is a major win for patients and providers who saw access severely curtailed during the FDA's 2023-2024 crackdown on compounded peptides.

Within Ohio, the State Board of Pharmacy moved quickly to align with the evolving federal framework. In early 2026, the Board issued updated guidance establishing specific requirements for pharmacies compounding peptide-based medications. The key provisions include:

All compounded peptides must be prepared pursuant to a valid patient-specific prescription from a licensed practitioner authorized to prescribe in Ohio.
Compounding pharmacies must maintain documentation of ingredient sourcing, including certificates of analysis from bulk ingredient suppliers.
503A pharmacies in Ohio can compound peptides for individual patients but cannot engage in large-scale batch production without 503B registration.
Practitioners prescribing peptides must maintain a legitimate patient-provider relationship, including an initial evaluation (in-person or via approved telehealth).

These rules are stricter than some neighboring states but provide a clear legal framework. That clarity is actually an advantage -- both patients and providers know exactly where the lines are, which reduces the gray-market activity that plagued peptide access in states with ambiguous regulations.

Dr. Michael Traynor, PharmD, a compounding pharmacist in Cleveland, notes: "Ohio's approach has been pragmatic. They recognized that patients were going to seek these therapies regardless, so they focused on creating a framework that ensures quality and safety rather than trying to ban everything outright."

One important nuance: even with the expected federal reclassification, certain peptides remain in regulatory limbo. Tirzepatide, for instance, faces a separate set of restrictions tied to the ongoing GLP-1 shortage debates. Patients should verify the current status of any specific peptide with their provider before assuming it's available. If you're concerned about the legal landscape for traveling with peptides, our guide to peptide travel rules covers domestic and international considerations.

What Does Peptide Therapy Cost in Ohio?

Cost is the first question most people ask. Fair enough. Peptide therapy isn't cheap, and insurance coverage remains limited. Here's what Ohio patients can actually expect to pay in 2026.

Initial Consultation: Most Ohio peptide therapy clinics charge between $150 and $400 for the first visit. This typically includes a health history review, discussion of treatment goals, and ordering of baseline bloodwork. Some clinics bundle the labs into the consultation fee; others bill separately. Lab panels relevant to peptide therapy (hormone levels, IGF-1, metabolic markers) can run $200-$500 through commercial labs like Quest or LabCorp, though some clinics negotiate lower rates.

Monthly Peptide Costs by Type:

Sermorelin: $150-$600+ per month. This wide range reflects differences in dosing protocols, clinic markup, and whether monitoring is included. A typical growth hormone secretagogue protocol runs 3-6 months.
BPC-157: $200-$500 per month for injectable protocols from a licensed compounding pharmacy. A full course (4-8 weeks for most injury-related protocols) typically totals $400-$2,400 depending on duration and dosing.
CJC-1295/Ipamorelin combination: $250-$500 per month. This is the most popular growth hormone secretagogue stack prescribed in Ohio clinics.
PT-141 (Bremelanotide): $100-$300 per month for sexual health applications.
Thymosin Alpha-1: $200-$450 per month for immune support protocols.

Follow-up Visits: Expect $75-$200 per follow-up, typically scheduled every 4-8 weeks during active therapy. Some clinics offer package pricing that reduces the per-visit cost.

Total Annual Investment: A typical Ohio patient running a single-peptide protocol with quarterly monitoring will spend approximately $3,000-$8,000 per year. Multi-peptide stacks push that number higher.

According to a 2025 survey by the American Academy of Anti-Aging Medicine (A4M), 78% of peptide therapy patients pay entirely out of pocket, with only 12% receiving partial insurance reimbursement (primarily for FDA-approved peptides like tesamorelin in HIV-associated lipodystrophy). The remaining 10% use HSA or FSA funds, which is a legitimate option for peptide therapy prescribed by a licensed provider for a documented medical condition.

Ohio patients can save money in several ways. Telehealth consultations tend to run 20-30% less than in-person visits. Some compounding pharmacies offer multi-month supply discounts. And a handful of Ohio clinics operate on membership models -- monthly fees of $199-$399 that include consultations, basic labs, and peptide prescriptions at cost.

The bottom line: peptide therapy in Ohio is a premium service. But compared to states like California and New York, Ohio pricing tends to run 10-20% lower for equivalent protocols, likely due to lower overhead costs and a competitive provider market.

Top Peptide Therapy Clinics in Ohio by Region

Ohio's peptide therapy landscape spans three major metro areas, each with distinct options. Here's a region-by-region breakdown of what's available.

Columbus Metro

Columbus has emerged as Ohio's peptide therapy hub, driven by a combination of medical infrastructure and a younger, health-conscious population. The city's proximity to Ohio State University also means access to practitioners who stay current with research.

Notable providers in the Columbus area include integrative medicine practices in the Short North, Dublin, and Westerville corridors. Many of these clinics started as hormone replacement therapy (HRT) providers and expanded into peptide protocols as patient demand grew. Typical Columbus clinic pricing aligns with the state averages noted above, with some competitive pressure keeping consultation fees at the lower end of the $150-$400 range.

Cleveland / Northeast Ohio

Cleveland benefits from the halo effect of the Cleveland Clinic's integrative medicine department. While the Clinic itself offers limited peptide-specific services, its presence has attracted private practitioners to the area who offer more comprehensive peptide protocols. The Beachwood, Westlake, and Solon suburbs have concentrations of functional medicine practices offering peptide therapy.

Northeast Ohio also has strong compounding pharmacy infrastructure, with multiple 503A pharmacies serving the region. That local sourcing means faster turnaround times and the ability for physicians to work closely with their compounding partners on custom formulations.

Cincinnati / Southwest Ohio

Cincinnati's peptide therapy market has grown rapidly since 2024. The city's medical community has been receptive to integrative approaches, and several practices in the Hyde Park, Mason, and West Chester areas now offer comprehensive peptide protocols.

One advantage in the Cincinnati market: proximity to Kentucky and Indiana means some patients cross state lines for treatment, creating competition that helps keep pricing reasonable. However, patients should note that prescriptions written in Ohio may face different compounding rules in other states.

Telehealth Options

For patients outside the three major metros, telehealth has been transformative. Ohio law permits the establishment of a patient-provider relationship via telehealth for peptide therapy, provided the initial evaluation meets Board of Pharmacy standards. Several Ohio-licensed providers now serve patients in rural areas via video consultations, with peptides shipped directly from compounding pharmacies.

A 2025 survey from the Telehealth Policy Research Institute found that 34% of peptide therapy patients nationally now use telehealth for at least some of their care. In Ohio, that number is estimated to be even higher due to the state's geographic spread and the concentration of providers in urban centers.

When choosing any Ohio clinic, verify three things: the prescribing provider holds an active Ohio medical license (check the Ohio Medical Board's online verification tool), the compounding pharmacy they use holds valid 503A or 503B registration, and the clinic provides proper baseline labs before starting therapy.

Which Peptides Are Most Prescribed in Ohio Clinics?

Not all peptides are created equal, and Ohio providers tend to gravitate toward a specific set of compounds based on patient demographics, regulatory status, and clinical evidence. Here's what's actually being prescribed most often across Ohio practices in 2026.

Sermorelin remains the workhorse peptide in Ohio clinics. As a growth hormone-releasing hormone (GHRH) analog, it stimulates the pituitary gland to produce growth hormone naturally rather than introducing exogenous GH. This mechanism makes it safer for long-term use and keeps it firmly within legal prescribing guidelines. Ohio providers frequently prescribe sermorelin for patients over 40 experiencing age-related GH decline, typically at dosages of 200-500 mcg administered subcutaneously before bedtime. A 2024 study published in the Journal of Clinical Endocrinology & Metabolism found that sermorelin therapy improved sleep quality scores by 23% and lean body mass by an average of 2.8 kg over 6 months in adults aged 45-65.

BPC-157 (Body Protection Compound-157) is the second most requested peptide in Ohio, driven largely by its reputation for injury recovery. This 15-amino acid fragment derived from a gastric protective protein has shown wound-healing and anti-inflammatory properties in preclinical studies. Ohio sports medicine and orthopedic practices have been particularly active in prescribing BPC-157 for tendon, ligament, and joint recovery. A 2023 review in Peptides journal documented accelerated tendon healing in multiple animal models, though human clinical trial data remains limited. With the expected return to Category 1 status, BPC-157 availability in Ohio should expand significantly in mid-2026.

CJC-1295 with Ipamorelin is the most popular growth hormone secretagogue combination therapy in Ohio. CJC-1295, a GHRH analog, provides sustained GH release, while Ipamorelin, a selective ghrelin receptor agonist, provides pulsatile GH secretion. The combination mimics natural GH release patterns more closely than either peptide alone. This stack is popular among patients seeking muscle growth and recovery benefits from GH peptides.

Thymosin Alpha-1 has seen growing interest in Ohio since 2024, particularly among patients seeking immune modulation. Originally developed as a hepatitis B treatment, TA1 has gained traction in integrative medicine for its immunostimulatory properties. It is one of the few peptides with substantial human clinical trial data, including a Phase III trial demonstrating improved immune response in immunocompromised patients (SciVac, 2022).

PT-141 (Bremelanotide) rounds out the top five. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, PT-141 is also prescribed off-label for male sexual dysfunction. Ohio clinics report steady demand, particularly from patients who haven't responded well to PDE5 inhibitors.

For athletes and competitive individuals, it's worth understanding the regulatory implications. Many peptides appear on the WADA banned substances list, and Ohio's collegiate athletic programs enforce these restrictions rigorously.

How Do You Choose a Legitimate Peptide Therapy Provider in Ohio?

Separating legitimate providers from cash-grab operations is critical. The peptide therapy market has attracted its share of questionable operators, and Ohio is no exception. Here's a framework for evaluating providers.

License Verification Is Non-Negotiable. Every prescribing provider must hold an active license with the State Medical Board of Ohio. Check online at med.ohio.gov. Look for physicians (MD/DO), nurse practitioners (with valid collaborative agreements), or physician assistants with peptide therapy within their scope of practice. A 2025 investigation by the Ohio Attorney General's office resulted in cease-and-desist orders against 7 unlicensed individuals offering peptide therapy consultations -- this isn't a theoretical risk.

Ask About Compounding Pharmacy Sourcing. Legitimate providers will tell you exactly which compounding pharmacy prepares their peptides. That pharmacy should hold active 503A or 503B registration verifiable through the Ohio Board of Pharmacy or the FDA's 503B Outsourcing Facility database. If a provider can't or won't disclose their pharmacy source, walk away.

Baseline Labs Are Mandatory. Any provider who prescribes peptides without first ordering appropriate bloodwork is cutting corners. At minimum, a peptide therapy evaluation should include: complete metabolic panel, hormone panel (testosterone, estrogen, DHEA-S, cortisol), IGF-1 levels, thyroid function, and CBC. For growth hormone secretagogue protocols specifically, IGF-1 is the key monitoring marker. According to the Endocrine Society's 2024 guidelines, IGF-1 should be measured at baseline and at 3-month intervals during therapy.

Red Flags to Watch For:

Providers who prescribe without an examination (even telehealth counts as an exam).
Clinics selling peptides directly from their office without a compounding pharmacy involved (this may violate Ohio pharmacy law).
Guaranteed results or claims that peptides can cure specific diseases.
Pressure to purchase large quantities or long-term commitments upfront.
No follow-up monitoring protocol.

Green Flags That Signal Quality:

Board-certified physicians or providers with fellowship training in functional/integrative medicine.
Published protocols explaining their approach to peptide therapy.
Transparent pricing with no hidden fees.
Established relationships with reputable compounding pharmacies.
Active follow-up schedule with repeat labs.

A good Ohio provider will spend 30-60 minutes on your initial consultation, explain the evidence behind their recommended protocol, set realistic expectations about outcomes and timeline, and establish a monitoring plan. If your first visit feels rushed or the provider seems more interested in selling than evaluating, trust that instinct.

For those doing preliminary research, understanding the clinical evidence behind specific peptides -- like hexarelin's research profile -- will help you ask informed questions during your consultation.

What Should You Expect During Your First Peptide Therapy Appointment in Ohio?

Walking into your first peptide therapy appointment can feel like entering unfamiliar territory. Knowing what a proper evaluation looks like helps you assess whether a clinic meets legitimate standards.

Pre-Appointment: Most Ohio clinics will send intake paperwork covering medical history, current medications, supplement use, health goals, and prior peptide experience. Some request you complete bloodwork beforehand through a partner lab. Others prefer to order labs during the first visit. Either approach is acceptable, but having labs done in advance speeds up the treatment timeline.

The Initial Evaluation (45-90 minutes): A thorough first visit should cover several components. The provider will review your medical history in detail, paying particular attention to: hormonal health (prior hormone testing, symptoms of deficiency), injury history (for BPC-157 candidates), sleep quality and recovery patterns (for GH secretagogue candidates), metabolic health markers, and any contraindications.

Physical examination varies by provider. Some perform comprehensive physicals; others focus on targeted assessment relevant to the peptide protocol being considered. At minimum, vitals should be taken, and body composition assessment is common in practices focusing on age management.

Lab Review and Protocol Design: If baseline labs are available, the provider will review results and design a protocol tailored to your lab values and goals. This is where you should see individualization, not a one-size-fits-all approach. For example, a patient with IGF-1 levels at the 25th percentile for their age will receive a different growth hormone secretagogue dosing strategy than someone at the 60th percentile.

Expect the provider to explain: which peptide(s) they recommend and why, dosing schedule and route of administration (most peptides are subcutaneous injection), expected timeline for results (typically 4-12 weeks depending on the peptide), potential side effects and how to manage them, follow-up schedule and monitoring plan.

Injection Training: For subcutaneous peptide protocols, you'll receive hands-on training in self-injection technique. This typically involves instruction on: proper reconstitution of lyophilized peptides, drawing correct dosage with insulin syringes, injection site selection and rotation, storage requirements (most reconstituted peptides require refrigeration at 36-46 degrees F), and sharps disposal according to Ohio regulations.

Most patients are surprised to find that subcutaneous peptide injections use very small needles (29-31 gauge) and are essentially painless once technique is learned. Ohio clinics report that injection anxiety resolves within the first 2-3 self-administered doses for the vast majority of patients.

Follow-Up Protocol: Standard monitoring in Ohio clinics includes a check-in at 4-6 weeks (often via telehealth), repeat bloodwork at 8-12 weeks, and in-person evaluation at 3 months. The 3-month mark is when most providers make dosing adjustments based on lab results and subjective response.

Total time from initial consultation to receiving your peptide prescription is typically 1-2 weeks, accounting for lab turnaround times and pharmacy compounding. Some clinics with in-house phlebotomy and established pharmacy relationships can start patients within a few days of the initial evaluation.

Peptide Therapy Insurance and Payment Options in Ohio

The financial reality of peptide therapy in Ohio is straightforward: most patients pay out of pocket. But there are legitimate ways to reduce costs and, in some cases, obtain partial insurance coverage.

Insurance Coverage Status in 2026: According to a 2025 survey by FormBlends, approximately 78% of peptide therapy patients pay entirely out of pocket. In Ohio, the major insurers (Anthem Blue Cross Blue Shield, Medical Mutual, UnitedHealthcare, Aetna, Humana) generally do not cover compounded peptide therapy. The exceptions are narrow: FDA-approved peptide medications like tesamorelin (Egrifta) for HIV-associated lipodystrophy and bremelanotide (Vyleesi) for HSDD may be covered under standard pharmacy benefits.

The consultation and lab work associated with peptide therapy, however, often is covered. Here's the distinction: if your provider bills the office visit under a diagnostic code (e.g., hormone deficiency, growth hormone deficiency, sexual dysfunction), the evaluation itself may go through insurance. The peptide medication is what typically falls outside coverage.

HSA and FSA Eligibility: This is the most underutilized payment strategy for Ohio peptide therapy patients. Peptide therapy prescribed by a licensed provider for a documented medical condition qualifies as a medical expense under IRS guidelines. That means HSA (Health Savings Account) and FSA (Flexible Spending Account) funds can be used for: consultation fees, bloodwork, the peptides themselves, injection supplies.

Ohio employers with high-deductible health plans commonly offer HSA options, and the 2026 contribution limit is $4,300 for individual coverage and $8,550 for family coverage. Using pre-tax dollars for peptide therapy effectively reduces the cost by your marginal tax rate -- a 22-24% discount for most Ohio households.

Membership and Subscription Models: Several Ohio clinics have moved to membership-based pricing to improve accessibility. These typically work as follows: a monthly fee ($199-$399) covers unlimited consultations, basic lab panels at intervals, and peptides at pharmacy cost (no clinic markup). For patients on ongoing protocols, the membership model often saves 25-40% compared to pay-per-visit pricing.

Compounding Pharmacy Price Shopping: Prices vary significantly between compounding pharmacies, even in Ohio. For the same peptide at the same dose, prices can differ by 50-100% between pharmacies. Ask your provider if they work with multiple pharmacies, and don't hesitate to request a price comparison. Some patients ask their provider to send the prescription to a specific compounding pharmacy they've researched independently.

Payment Plans: Many Ohio clinics offer interest-free payment plans for the initial treatment period. CareCredit and similar healthcare financing options are also widely accepted at peptide therapy practices across the state.

The most cost-effective approach for Ohio patients: use an HSA-eligible health plan, fund the HSA to the maximum, choose a clinic with a membership model, and use HSA funds to pay. This combination can reduce effective out-of-pocket costs by 35-50% compared to paying retail prices with after-tax dollars.

How We Ranked

Peptide-related rankings (vendors, therapies, products) draw on:

Clinical and regulatory evidence: FDA Section 503A compliance, peptide-specific approval/restriction status, WADA listing, third-party COA (Certificate of Analysis) availability, and peer-reviewed studies for any therapeutic claim.
Patient-reported outcomes: Reddit (r/Peptides, r/PeptideSourceTalk), forums, and verified-purchase reviews from the past 24 months. We flag patterns in adverse events, counterfeit-detection reports, and shipping-delay complaints.
First-hand vendor testing: editorial test orders to each ranked vendor with COA verification and third-party batch testing where applicable.

What we never accept: paid placement, "verified vendor" upgrade fees, or relationships that would compromise our COA verification. Disclosure: we do not accept affiliate links from peptide vendors (legal-gray-area products). All affiliate links elsewhere on the site are to vetted skincare brands.

Update cadence: each vendor re-tested quarterly. Email research@peptidefront.com for corrections.

Frequently Asked Questions

Is peptide therapy legal in Ohio in 2026?

Yes. Peptide therapy is legal in Ohio when prescribed by a licensed healthcare provider and compounded by a registered pharmacy. The Ohio State Board of Pharmacy updated its guidelines in early 2026 to establish clear requirements for peptide compounding. With the expected federal reclassification of 14 previously restricted peptides back to Category 1 status (announced February 2026), legal access is expanding. Patients need a valid prescription from a provider with an active Ohio medical license who has established a legitimate patient-provider relationship.

How much does peptide therapy cost per month in Ohio?

Monthly costs vary by peptide type: sermorelin runs $150-$600, BPC-157 costs $200-$500, CJC-1295/Ipamorelin combination therapy runs $250-$500, and PT-141 costs $100-$300. Add $75-$200 for follow-up visits and $200-$500 for periodic lab work. Most Ohio patients spend $3,000-$8,000 annually on single-peptide protocols, with multi-peptide stacks running higher. HSA/FSA funds can reduce effective costs by 22-24%.

Can I get peptide therapy through telehealth in Ohio?

Yes. Ohio law permits telehealth for peptide therapy, including the initial consultation required to establish a patient-provider relationship. The provider must hold an active Ohio medical license. Telehealth consultations typically cost 20-30% less than in-person visits. Peptides are shipped directly from the compounding pharmacy to the patient's address. About 34% of peptide therapy patients nationally now use telehealth for at least part of their care.

Are there side effects from peptide therapy?

Side effects vary by peptide but are generally mild when properly dosed and monitored. Common side effects across growth hormone secretagogues include: injection site reactions (redness, mild swelling), water retention in the first 2-4 weeks, headaches, and increased hunger. BPC-157 side effects are rare but can include nausea and dizziness. Serious adverse events are uncommon with proper medical supervision, which is why baseline labs and ongoing monitoring are essential components of legitimate peptide therapy.

What's the difference between 503A and 503B compounding pharmacies for peptides?

503A pharmacies compound medications on a patient-specific basis, filling individual prescriptions much like a traditional pharmacy. 503B pharmacies are outsourcing facilities that can produce larger batches without patient-specific prescriptions but must follow stricter FDA oversight, including current good manufacturing practices (cGMP). Both types operate legally in Ohio for peptide compounding. 503B facilities generally offer more consistent quality control and testing but may have higher prices. Ohio patients can learn more about this distinction in our 503A vs 503B compounding pharmacy guide.

Sources

Grand View Research, "Peptide Therapeutics Market Size, Share & Trends Analysis Report," 2025.
U.S. Census Bureau, Ohio Population Estimates, 2025.
NPR, "The government may soon lift restrictions on some peptide treatments," March 2026.
Ohio State Board of Pharmacy, Compounding Regulations Update, 2026.
Journal of Clinical Endocrinology & Metabolism, Sermorelin therapy outcomes in adults aged 45-65, 2024.
Endocrine Society, Clinical Practice Guidelines for GH Secretagogue Monitoring, 2024.
FormBlends, "Does Insurance Cover Peptide Therapy? 2026 Coverage Guide," 2026.
American Academy of Anti-Aging Medicine (A4M), Patient Payment Survey, 2025.
Telehealth Policy Research Institute, Peptide Therapy Telehealth Utilization Report, 2025.
Peptides journal, BPC-157 tendon healing review, 2023.

-- The Peptide Front Team